Clinical evaluation demonstrates potential delayed disease progression in primary HIV-1 infection, suggesting benefits of early antiretroviral therapy.
Short-course antiretroviral therapy (ART) in primary human immunodeficiency virus (HIV) infection may delay disease progression but has not been adequately evaluated.
No takes yet. Share an insight, caveat, or question.
Brady et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: